# Revvity

**Source:** https://geo.sig.ai/brands/revvity  
**Vertical:** Healthcare Tech  
**Subcategory:** Life Science Tools & Diagnostics  
**Tier:** Leader  
**Website:** revvity.com  
**Last Updated:** 2026-04-14

## Summary

Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.

## Company Overview

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.

Revvity reported approximately $2.9 billion in revenue in FY2024, following the divestiture of its Applied, Food, and Enterprise Services segment (sold to New Mountain Capital in 2023 for $2.45 billion) to sharpen focus on higher-growth life science and diagnostics markets. The Diagnostics segment's newborn screening franchise — screening for ~50+ metabolic disorders using Revvity's NeoBase kits and Natus instruments — has near-monopoly characteristics in many countries where national programs are standardized on Revvity platforms. The Life Sciences segment serves pharmaceutical and biotech researchers with automated liquid handling, imaging systems, and genomics tools.

Revvity's strategic priority is integrating its informatics capabilities (Symphony, OneSource laboratory software) with its instrument platforms to create connected lab ecosystems. The company's EUROIMMUN diagnostics business, acquired in 2017 for €1.3 billion, is a leading provider of autoimmune and infectious disease diagnostics in Europe, strengthening its clinical diagnostics presence.

## Frequently Asked Questions

### What does Revvity do?
Revvity provides life science instruments, reagents, and software for drug discovery and genomics research, plus diagnostic systems for newborn screening, reproductive health, and clinical testing. It is the global leader in newborn metabolic disorder screening.

### Why was PerkinElmer rebranded to Revvity?
PerkinElmer rebranded as Revvity in 2023 after selling its applied, food, and industrial testing businesses to refocus on life sciences and diagnostics. The new brand signals a higher-growth, biology-focused identity rather than a broad instruments conglomerate.

### What is Revvity's ticker?
Revvity Inc. trades on the NYSE under the ticker RVTY.

### What is Revvity's newborn screening business?
Revvity is the global leader in newborn screening programs that test babies for 50+ metabolic, genetic, and endocrine disorders within 24–48 hours of birth. Its NeoBase kits, instruments, and software are used by national health programs across dozens of countries.

### What genomics and drug discovery instruments does Revvity offer?
Revvity provides next-generation sequencing (NGS) library prep systems, single-cell biology instruments, high-content imaging systems for drug screening, and automated liquid handling platforms for genomics workflows. In drug discovery, Revvity's HTRF assay technology and AlphaLISA bead-based detection systems are widely used for target engagement and compound screening. These platforms are used by pharmaceutical and biotech companies to accelerate the early-stage research that identifies drug candidates.

### How does Revvity's diagnostic business complement its life science tools?
Revvity's diagnostics division provides clinical testing systems for hospital and reference laboratories, including infectious disease, allergy, and autoimmune testing alongside its flagship newborn screening program. The diagnostics business generates more recurring revenue than instrument sales (reagent kits are consumable) and creates direct relationships with clinical laboratories — a different customer base than the research laboratory market served by the life science tools division.

### What is Revvity's global newborn screening program scope?
Revvity's NeoBase and PerkinElmer-branded newborn screening systems are used in national programs across 60+ countries, screening tens of millions of newborns annually. These programs identify babies with potentially fatal metabolic conditions like PKU (phenylketonuria), congenital hypothyroidism, and 50+ other disorders within 24-48 hours of birth, enabling treatment before symptoms appear. Revvity is the primary global vendor for this screening infrastructure.

### What is Revvity's strategy following the PerkinElmer rebrand?
The rebrand to Revvity signals a strategic focus on higher-growth, biology-centric businesses — genomics, drug discovery tools, and diagnostics — following the sale of PerkinElmer's lower-growth applied, food testing, and industrial segments. The new brand is designed to attract talent and investor attention as a pure-play life science company rather than a diversified instruments conglomerate. The strategy prioritizes margin expansion and portfolio focus over revenue diversification.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*